PREPARE FOR THE WINTER RESPIRATORY SEASON

Confident Diagnostics When Time Matters Most. From Cepheid

Winter brings a surge in respiratory infections, and with it, the need for fast, dependable diagnostics. Whether you're managing routine cases or urgent samples, having the right tools in place can make all the difference, for both your teams and your patients. The Cepheid Xpert® Xpress CoV-2/Flu/RSV plus test is designed to simplify respiratory diagnostics by detecting multiple pathogens in a single, rapid test, in just 36 minutes. Results are delivered with precision and speed, helping clinicians make timely decisions and improve patient outcomes.

 

To take advantage of all these benefits, all you need is: an instrument, a patient sample, and a cartridge. No additional reagents or complex preparation required. And you can count on us, our experts are never far away whenever you need assistance. From installation to training, Cepheid supports you every step of the way, so you can start testing with confidence.

 

Ready to Strengthen Your Respiratory Testing Strategy?

Explore how Cepheid’s solutions can help you stay ahead this season.

 

GETTING STARTED

Our Innovative Solution

ONE PLATFORM. ENDLESS POSSIBILITIES.

A System That Adapts to You

The GeneXpert® family of systems is Cepheid’s scalable molecular platform built for high-performance 24/7 testing. Whether you're running a small clinic or a large hospital, choose from 2 to 80 modules to match your testing volume and space.

ONE TEST. MULTIPLE ANSWERS.

A Lab in a Cartridge™

Reliably detect and differentiate SARS-CoV-2, influenza A & B, and RSV from a single sample in just 36 minutes with the Xpert Xpress CoV-2/Flu/RSV plus test. Built with a multi-gene target approach, it offers robust detection even as viral strains evolve.

ONE PROCESS. THREE EASY STEPS.

A Simple Workflow

Cepheid’s solutions are designed for simplicity, requiring minimal training and hands-on time. With intuitive workflows and automated processes, even complex molecular diagnostics become accessible, freeing up your highly skilled staff to focus on critical tasks.

 

WHY DO WE CALL IT "LAB IN A CARTRIDGE"

1 Cartridge. 4 Disease States. 10 Genetic Targets. 41 Primers/Probes

Xpert Xpress CoV-2/Flu/RSV plus offers a single test for SARS-CoV-2, Flu A, Flu B and RSV that ensures extended coverage to prevent impact of circulating mutations.

 
 

SARS-CoV-2

  • RdRP RNA-dependent RNA polymerase gene
  • E Envelope protein gene
  • N2 Nucleocapsid gene

Flu A

  • M Matrix gene
  • PB2 polymerase basic protein 2 gene
  • PA polymerase acidic protein gene

Flu B

  • M Matrix gene
  • NS non-structural protein gene

RSV

  • RSV A Nucleocapsid gene
  • RSV B Nucleocapsid gene
 

THE IMPACT

Improve Patient Outcomes and Your Lab Efficiency

At Cepheid, we believe that technology should make a meaningful impact. Our goal is to make molecular diagnostic testing accessible and practical, helping healthcare providers deliver better care. That’s why the Xpert® Xpress CoV-2/Flu/RSV plus test stands out:

 

  • Xpert Xpress CoV-2/Flu/RSV plus allows for accurate and rapid results, optimising diagnostic efficiency and improving the provision of appropriate treatment1
  • Testing with Xpert Xpress CoV-2/Flu/RSV plus may result in significant cost-savings compared to antigen and send-out PCR testing strategies and may result in fewer hospitalisations, ICU admissions, mechanical ventilations, and deaths compared to antigen and send-out PCR testing strategies1
  • Gives the right result first time, reducing the need for reflex and/or confirmatory testing2

 

EASY SETUP

Order Now, Start Testing in the Autumn

-1-

Contact Us

Fill the form below and your Cepheid Representative will get back to you as soon as possible

-2-

Tailor Your Solution

Your Cepheid Representative will work with you to understand your challenges and present you the solution that will best fit your needs

-3-

Sign Your Contract

Your Cepheid Representative will help you finalise the details of the agreement so that you can get started as soon as possible

-4-

Install Your Instrument

On a date that you will have previously set, your Field Application Specialist will come and set up your instrument, and will provide a training

-5-

Train Your Teams

You will be able to train all potential users in your institution and run the specific applicable procedures if any. Your FAS will accompany during those steps if needed

-6-

Start Testing

Congratulations! You are all set: you can collect a first patient sample with the appropriate collection device and run your first test

Still Have Some Questions?

Every institution is different and these projects can sometimes seem complex. Feel free to reach out to us if you have any doubt on how our solutions can help you.

WE ARE HERE TO HELP

Contact Us Now

I would like to be part of the Cepheid Community and I understand and consent to receive information about products and services, invitations to virtual and in-person events such as workshops and webinars and educational content from Cepheid and similar information from Cepheid’s affiliates and representatives.

*required fields
Cepheid respects your privacy, and values the relationship with our customers, partners, and associates. Your personal data may be processed by Cepheid, its affiliates, representatives and other Danaher companies for business and marketing purposes. You can review Cepheid Privacy Policy online for additional information on your rights and how we use and share personal data we collect on our websites and other channels. Your consent to receiving Cepheid news can be withdrawn at any time. Building a relationship of trust is important to us and we will happily help with any questions on your personal data processing addressed to Privacy.officer@cepheid.com

CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries.

1. Davies, E. Boller, A. Beaubrun, C. Miller, I. Jensen. (2023) A Cost-Consequence Analysis of Xpert Xpress CoV-2/Flu/RSV Plus for the Diagnosis of Viral Respiratory Infections from a US Health Plan Perspective.J Mol Diagn, 25(11) (S1-S186): S64. https://www.jmdjournal.org/article/S1525-1578%2823%2900249-0/pdf
2. K. Stockl, J. Tucker, J. Certa, A. Beaubrun, K. Schwebke. (2023). Use of Antigen and Molecular Testing for Coronavirus 2019 (SARS-CoV-2) among Patients with Influenza-Like Illness (ILI) in the Non-inpatient Setting. J Mol Diagn, 25(11) (S1-S186): S53. https://www.jmdjournal.org/article/S1525-1578%2823%2900249-0/pdf

About Cepheid

Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid's broad test portfolio spans respiratory infections, blood virology, women's and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company's solutions deliver actionable results where they are needed most from central laboratories and hospitals to near patient settings.

For more information, visit www.cepheid.com

©2025 Cepheid. All Rights Reserved.